• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Albunex wins European panel's nod

Article

Molecular Biosystems has received an approval recommendation fromEurope's Committee for Proprietary Medicinal Products (CPMP) forits Albunex ultrasound contrast agent, which will be marketedin Europe as Infoson. Infoson's application will now go to

Molecular Biosystems has received an approval recommendation fromEurope's Committee for Proprietary Medicinal Products (CPMP) forits Albunex ultrasound contrast agent, which will be marketedin Europe as Infoson. Infoson's application will now go to membercountries of the European Union, whose regulatory agencies generallyfollow CPMP recommendations.

San Diego-based MBI took over regulatory responsibility forInfoson after it reacquired European marketing rights to the agentlate last year from Hafslund Nycomed, which had shepherded Infosonthrough European clinical trials. Nycomed apparently wished tofocus on commercial development of its own ultrasound contrastagents, according to MBI president and COO Bobba Venkatadri.

MBI is looking for another marketing partner to handle Infosonin the regions once covered by Nycomed: Europe, Africa, the MiddleEast, India, and the former Soviet Union. MBI is in discussionswith several firms, including U.S. marketing partner MallinckrodtMedical, and hopes to have a deal sewn up by May, Venkatadri said.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.